Description: Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.
Home Page: www.medexus.com
10 King Street East
Toronto,
ON
M5C 1C3
Canada
Phone:
877 422 5242
Officers
| Name | Title |
|---|---|
| Mr. Kenneth d'Entremont | CEO & Director |
| Mr. Richard Labelle | Chief Operating Officer |
| Mr. Ian C. Wildgoose Brown | General Counsel & Corporate Secretary |
| Mr. Brendon Buschman | Chief Financial Officer |
| Ms. Tina Byers CFA | Executive of Investor Relations |
| Mr. Bill Poncy | Senior Vice President of Commercial Operations - United States |
| Mr. Brian Peters | Vice President of Sales & Marketing - United States |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 15.4321 |
|---|---|
| Trailing PE: | 23.75 |
| Price-to-Book MRQ: | 1.5143 |
| Price-to-Sales TTM: | 0.4517 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 82 |